Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377588 | 0.90 | CHRM4 (0.45) | CHRM4MLNRFAAHAGTR2ADAMTS5 | |
| SCHEMBL377489 | 0.84 | MLNR (0.41) | MLNRFAAH | |
| SCHEMBL2397558 | 0.82 | MLNR (0.46) | MLNRFAAHAGTR2ACHE | |
| SCHEMBL377748 | 0.82 | MLNR (0.49) | MLNRFAAH | |
| SCHEMBL377854 | 0.79 | MLNR (0.47) | MLNRFAAH | |
| SCHEMBL3911284 | 0.78 | MLNR (0.47) | CHRM4MLNRFAAHSLC18A3SIGMAR1 | |
| SCHEMBL2397562 | 0.78 | MLNR (0.39) | MCHR1MLNRFAAHSIGMAR1 | |
| SCHEMBL3559659 | 0.78 | MLNR (0.49) | MCHR1MLNR | |
| SCHEMBL2393780 | 0.77 | FAAH (0.40) | MLNRFAAH | |
| SCHEMBL2396382 | 0.77 | MLNR (0.43) | MLNRFAAHACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029538-B1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | SEAL JONATHAN THOMAS | 2011-11-10 | — | — | US | disclosed |
| US-8012981-B2 | Benzylpiperazine derivatives as motilin receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | CHRM4 395/4885MCHR1 66/4885MLNR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.